For Healthcare Professionals

Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

clipboard-pencil

About the study

Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. White Brazilian of European descent
  2. Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD
  3. Eligibility to immediate-release MPH (IR-MPH) treatment

EXCLUSION CRITERIA

  1. Contraindication for IR-MPH use
  2. Current stimulant treatment
  3. Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)
  4. Current or past history of psychosis
  5. Estimated intelligence quotient score lower than 70
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall +55 51 3359-8094Email iconEmail Study Center

Study’s details


Contition

Attention Deficit Disorder With Hyperactivity

Age

18+

Phase

Phase 4

Participants needed

600

Est. Completion Date

Dec 2032

Treatment type

Interventional


Sponsor

Hospital de Clinicas de Porto Alegre

ClinicalTrials.gov identifier

NCT02951754

Study number

100358

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.